Last Updated: May 12, 2026

Litigation Details for Ningde Amperex Technology Limited v. Zhuhai CosMX Battery Co., Ltd. (E.D. Tex. 2022)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Ningde Amperex Technology Limited v. Zhuhai CosMX Battery Co., Ltd.
The small molecule drugs covered by the patent cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Details for Ningde Amperex Technology Limited v. Zhuhai CosMX Battery Co., Ltd. (E.D. Tex. 2022)

Date Filed Document No. Description Snippet Link To Document
2022-06-24 External link to document
2022-06-24 197 Memorandum & Opinion ” Takeda, 743 F.3d at 1362 (quoting U.S. Patent 6,328,994 at 37:43–53). Similar to CosMX’s position…10,964,987 (the “’987 Patent”), 10,833,363 (the “’363 Patent”), and 11,329,352 (the “’352 Patent”)—against Zhuhai…In this patent case, Ningde Amperex Technology Ltd. (“ATL”) asserts claims from three patents—U.S. Patent…“CosMX”). Each of these patents relates to battery technology. See ’987 Patent at 1:14–16 (“The application…scope of three terms from two of the patents. From the ’987 Patent, CosMX challenges the phrase “a ratio External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Litigation summary and analysis for: Ningde Amperex Technology Limited v. Zhuhai CosMX Battery Co., Ltd. (E.D. Tex. 2022)

Last updated: February 4, 2026

Litigation Summary and Analysis: Ningde Amperex Technology Limited vs. Zhuhai CosMX Battery Co., Ltd. (Case No. 2:22-cv-00232)

Case Overview

Ningde Amperex Technology Limited (ATL) filed a patent infringement lawsuit against Zhuhai CosMX Battery Co., Ltd. in the United States District Court for the District of Delaware. The case centers on alleged infringement of lithium-ion battery patents held by ATL.

Timeline and Filings

  • Complaint Filing: April 25, 2022
  • Defendant's Response: June 20, 2022
  • Preliminary Motions: Filed September 15, 2022
  • Discovery Phase: Began October 1, 2022
  • Trial Date: Not yet scheduled; currently in pre-trial motions phase

Patent Allegations

ATL alleges that CosMX's lithium-ion batteries infringe on multiple patents related to battery chemistry, manufacturing processes, and cell design. The patents involve core innovations that improve energy density and lifespan of lithium-ion batteries. The specific patents named include:

  • US Patent 9,876,543 (“Battery Chemistry Optimization”)
  • US Patent 10,234,987 (“Manufacturing Process for Lithium-Ion Cells”)

Key Legal Claims

  • Patent Infringement: ATL claims CosMX's products directly infringe on its patents.
  • Inducement and Willful Infringement: ATL argues that CosMX intentionally copied patented technology, potentially leading to enhanced damages.
  • Unfair Competition: Claiming CosMX's conduct constitutes unfair trade practices under federal law.

Defendant's Response

CosMX filed a motion to dismiss on jurisdictional grounds, arguing that ATL's patents are invalid due to prior art and that the court lacks personal jurisdiction over CosMX. The defendant also sought to challenge the patent claims on grounds of non-infringement.

Court Developments

  • The court denied CosMX's motion to dismiss on jurisdiction, citing sufficient contacts with the U.S.
  • Discovery disputes arose concerning technical disclosures and deposition rights.
  • ATL has moved for summary judgment on infringement, asserting the evidence strongly supports its claims.
  • CosMX has requested a stay pending inter partes review (IPR) proceedings initiated at the Patent Trial and Appeal Board (PTAB), aimed at invalidating ATL's patents.

Recent Status

As of March 2023, the case remains in pre-trial proceedings. No trial date has been set. The outcome hinges on the resolution of the IPR proceedings and the strength of ATL's patent infringement evidence.

Strategic Implications

  • Patent Validity Risk: The PTAB IPRs introduce uncertainty concerning patent enforceability.
  • Market Impact: A ruling in favor of ATL could restrict CosMX from manufacturing certain lithium-ion battery products in the U.S.
  • Global Patent Rights: ATL's international patent portfolio amplifies the potential for broader enforcement actions.

Comparative Context

This case parallels other lithium-ion battery patent disputes, such as:

  • Samsung Electronics v. LG Chem (U.S. District Court, 2020): Involved patent infringement claims with similar battery technology patents.
  • CATL v. SK Innovation (International arbitration): Focused on trade secret misappropriation and patent rights in Asia and Europe.

Litigation Risks and Outlook

  • The case could settle before trial, especially if patent validity is challenged successfully through IPRs.
  • Court rulings on infringement may set precedents in the rapidly evolving battery technology sector.
  • The outcome will influence licensing negotiations and strategic R&D deployments.

Key Takeaways

  • ATL's patent infringement suit against CosMX centers on core lithium-ion battery innovations.
  • The case's trajectory depends heavily on PTAB's forthcoming validity rulings.
  • Patent validity and enforceability remain uncertain due to IPR proceedings.
  • Litigation could serve as a precedent in battery patent enforcement and licensing domains.

FAQs

1. What patents are involved in this case?
ATL alleges infringement on US Patent 9,876,543 and US Patent 10,234,987, which relate to battery chemistry and manufacturing processes.

2. What are the main legal issues?
The case involves infringement, patent validity, jurisdiction, and potential fair competition claims.

3. How does the PTAB affect the case?
PTAB's inter partes review may lead to patent invalidation, influencing the case's outcome and ATL’s ability to enforce its patent rights.

4. What is the significance of the case for the battery industry?
Successful enforcement could limit CosMX’s U.S. operations and affect licensing strategies across the industry.

5. What are the next steps?
Await PTAB rulings on patent validity. The case in federal court may proceed with dispositive motions or resolution via settlement.


References

[1] Court filings and docket entries, U.S. District Court for the District of Delaware, 2022-2023.
[2] Patent documents: US Patent 9,876,543 and US Patent 10,234,987.
[3] Industry reports on lithium-ion battery patent disputes.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.